Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT00446940
NCT00446940CompletedPhase 2

Dose Finding Trial of Rosuvastatin and Atorvastatin Versus Hepatitis C

Bader, Ted, M.D.2 sites in 1 country16 target enrollmentStarted: December 1, 2006Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Drugs

Trial Snapshot

Phase
Phase 2
Status
Completed
Sponsor
Enrollment
16
Locations
2
Study OverviewStudy DesignEligibility CriteriaInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

Different Doses of rosuvastatin and atorvastatin will be used to see if HCV viral load changes and liver tests change.

Study Design

Study Type
Interventional
Allocation
Non Randomized
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to 75 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Hepatitis C

Exclusion Criteria

  • •HIV positivity

Investigators

Sponsor
Bader, Ted, M.D.
Sponsor Class
Indiv

Study Sites (2)

Loading locations...

Similar Trials

Completed
Phase 2
Assessment of the Antiviral Effect of Atorvastatin on Hepatitis C VirusHepatitis C
NCT00403533Massachusetts General Hospital10
Completed
Phase 3
STELLAR-Rosuvastatin vs. Atorvastatin, Pravastatin, Simvastatin Across Dose RangesHypercholesterolemia
NCT00654537AstraZeneca5,625
Unknown
Not Applicable
Effect of Statin Preloading in STEMI in Improving PCI OutcomesST Elevation Myocardial Infarction
NCT04974814Beni-Suef University99
Active, not recruiting
Phase 4
Comparative Study of Rosuvastatin/Ezetimib 20/10 mg and Atovastatin/Ezetimib 40/10 mg (TOLERANT Trial)DyslipidemiasCoronary Artery Disease
NCT05910476Yonsei University200
Unknown
Phase 3
Statin Adjunct Therapy Among ART-treated Adults in Sub-Saharan Africa: Atorvastatin and Rosuvastatin Equivalence TrialHIV Infection
NCT03037372Makerere University320